Development and Content Validity Evaluation of the Condition-Agnostic Treatment Goal Evaluation Scale (TGES) for Use...

Patient-reported outcomes (PROs) are important for understanding patients' experiences with their health conditions; however, individual perspectives of meaningful change for personalized treatment goals are rarely captured. Consequently, treatment outcomes assessed in clinical trials or routine practice may not align with real-world priorities or reflect individual perspectives. To bridge this gap, we developed the 2-part treatment goal evaluation scale (TGES) to assess individuals' perspectives of whether meaningful within-patient change has occurred in their self-identified treatment goal.

The draft TGES measure included the TGES - Baseline-a single, open-ended item to identify patients' primary treatment goal when starting a new treatment for a new or ongoing condition-and the TGES - Follow-Up-2 items designed to assess patients' perspectives of whether meaningful change has occurred in their self-identified goal and overall condition. Three rounds of qualitative interviews with adults aged ≥18 years with either atopic dermatitis (AD) or migraine were conducted to revise the draft TGES and assess content validity.

A total of 28 participants with AD (n=15) or migraine (n=13) were included; most identified as female (60.7%) and White (78.6%). Most participants interpreted the TGES - Baseline instructions (82.1%) and item (96.4%) as intended, whereas 39.3% suggested revisions to the instructions. Overall goal categories were identified: 3 AD-specific (improving physical symptoms, sensory symptoms, and choice of clothing) and 4 migraine-specific (reduced migraine frequency, impact on activities, migraine severity, and associated symptoms other than headache). Most participants interpreted the TGES - Follow-Up instructions (100.0%) and items (96.4%; 75.0%) as intended, with minor revisions suggested to improve clarity.

Qualitative interviews supported the content validity of the TGES for identifying individual treatment goals and assessing perspectives of meaningful change. With future quantitative evaluation, the patient-centric and condition-agnostic TGES may help evaluate personalized endpoints and inform within-patient meaningful change in clinical trial and real-world settings.